scholarly journals Construction of homogeneous antibody–drug conjugates using site-selective protein chemistry

2016 ◽  
Vol 7 (5) ◽  
pp. 2954-2963 ◽  
Author(s):  
Padma Akkapeddi ◽  
Saara-Anne Azizi ◽  
Allyson M. Freedy ◽  
Pedro M. S. D. Cal ◽  
Pedro M. P. Gois ◽  
...  
Keyword(s):  
Therapeutic Efficacy ◽  
Protein Chemistry ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Drug Conjugation ◽  
Selective Chemical ◽  
Site Selective ◽  
Antibody Drug

The use of site-selective chemical drug-conjugation strategies enables the construction of antibody–drug conjugates (ADCs) with superior therapeutic efficacy.”

ChemInform Abstract: Construction of Homogeneous Antibody-Drug Conjugates Using Site-Selective Protein Chemistry

ChemInform ◽  
2016 ◽  
Vol 47 (25) ◽  
Author(s):  
Padma Akkapeddi ◽  
Saara-Anne Azizi ◽  
Allyson M. Freedy ◽  
Pedro M. S. D. Cal ◽  
Pedro M. P. Gois ◽  
...  
Keyword(s):  
Protein Chemistry ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Site Selective ◽  
Antibody Drug

scholarly journals A general approach for the site-selective modification of native proteins, enabling the generation of stable and functional antibody–drug conjugates

2019 ◽  
Vol 10 (3) ◽  
pp. 694-700 ◽  
Author(s):  
Stephen J. Walsh ◽  
Soleilmane Omarjee ◽  
Warren R. J. D. Galloway ◽  
Terence T.-L. Kwan ◽  
Hannah F. Sore ◽  
...  
Keyword(s):  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Native Proteins ◽  
Site Selective ◽  
Antibody Drug

Divinylpyrimidine (DVP) linkers enable access to highly stable and functional antibody–drug conjugates.

scholarly journals Influence of disulfide bond isoforms on drug conjugation sites in cysteine-linked IgG2 antibody-drug conjugates

mAbs ◽  
2018 ◽  
Vol 10 (4) ◽  
pp. 583-595 ◽  
Author(s):  
Lily Liu-Shin ◽  
Adam Fung ◽  
Arun Malhotra ◽  
Gayathri Ratnaswamy
Keyword(s):  
Disulfide Bond ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Drug Conjugation ◽  
Igg2 Antibody ◽  
Antibody Drug

scholarly journals Site-selective modification strategies in antibody–drug conjugates

2021 ◽  
Author(s):  
Stephen J. Walsh ◽  
Jonathan D. Bargh ◽  
Friederike M. Dannheim ◽  
Abigail R. Hanby ◽  
Hikaru Seki ◽  
...  
Keyword(s):  
Cell Types ◽  
Specific Cell ◽  
Antibody Drug Conjugates ◽  
Specific Targeting ◽  
Drug Conjugates ◽  
Site Selective ◽  
Antibody Drug ◽  
Made In

Antibody–drug conjugates (ADCs) harness the highly specific targeting capabilities of an antibody to deliver a cytotoxic payload to specific cell types. This review summarises the advances made in the construction of homogenous ADCs.

scholarly journals Antibody-Drug Conjugates: Patient and Treatment Selection

2020 ◽  
pp. 105-114
Author(s):  
Shalini Makawita ◽  
Funda Meric-Bernstam
Keyword(s):  
Patient Selection ◽  
Therapeutic Efficacy ◽  
Antigen Expression ◽  
Therapeutic Modality ◽  
Intratumor Heterogeneity ◽  
Target Antigen ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
The Impact ◽  
Antibody Drug

Antibody-drug conjugates (ADCs) are a promising drug platform designed to enhance the therapeutic index and minimize the toxicity of anticancer agents. ADCs have experienced substantial progress and technological growth over the past decades; however, several challenges to patient selection and treatment remain. Methods to optimally capture all patients who may benefit from a particular ADC are still largely unknown. Although target antigen expression remains a biomarker for patient selection, the impact of intratumor heterogeneity on antigen expression, as well as the dynamic changes in expression with treatment and disease progression, are important considerations in patient selection. Better understanding of these factors, as well as minimum levels of target antigen expression required to achieve therapeutic efficacy, will enable further optimization of selection strategies. Other important considerations include understanding mechanisms of primary and acquired resistance to ADCs. Ongoing efforts in the design of its constituent parts to possess the intrinsic ability to overcome these mechanisms, including use of the “bystander effect” to enhance efficacy in heterogeneous or low target antigen-expressing tumors, as well as modulation of the chemical and immunophenotypic properties of antibodies and linker molecules to improve payload sensitivity and therapeutic efficacy, are under way. These strategies may also lead to improved safety profiles. Similarly, combination strategies using ADCs with other cytotoxic or immunomodulatory agents are also under development. Great strides have been made in ADC technology. With further refinements, this therapeutic modality has the potential to make an important clinical impact on a wider range of tumor types.

Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody–Drug Conjugates in Rats

2011 ◽  
Vol 22 (10) ◽  
pp. 1994-2004 ◽  
Author(s):  
C. Andrew Boswell ◽  
Eduardo E. Mundo ◽  
Crystal Zhang ◽  
Daniela Bumbaca ◽  
Nicole R. Valle ◽  
...  
Keyword(s):  
Tissue Distribution ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Drug Conjugation ◽  
Antibody Drug

scholarly journals Correction: A general approach for the site-selective modification of native proteins, enabling the generation of stable and functional antibody–drug conjugates

2019 ◽  
Vol 10 (2) ◽  
pp. 633-634
Author(s):  
Stephen J. Walsh ◽  
Soleilmane Omarjee ◽  
Warren R. J. D. Galloway ◽  
Terence T.-L. Kwan ◽  
Hannah F. Sore ◽  
...  
Keyword(s):  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Native Proteins ◽  
Site Selective ◽  
Antibody Drug

Correction for ‘A general approach for the site-selective modification of native proteins, enabling the generation of stable and functional antibody–drug conjugates’ by Stephen J. Walsh et al., Chem. Sci., 2019, DOI: 10.1039/c8sc04645j.

Sign in / Sign up

Export Citation Format

Share Document